PRTO Proteon Therapeutics Inc.

0.28
0  -2%
Previous Close 0.29
Open 0.28
Price To Book -0.47
Market Cap 5,503,496
Shares 19,585,394
Volume 519,066
Short Ratio
Av. Daily Volume 514,755

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 13, 2016 - primary endpoint not met.
Vonapanitase (PRT-201) PATENCY-1
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3 data released Match 28, 2019 did not meet primary endpoint.
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 1 enrolment to be completed by the end of 2019.
Vonapanitase (PRT-201)
Peripheral artery disease (PAD)

Latest News

  1. Proteon Therapeutics Announces Second Quarter 2019 Financial Results
  2. Those Who Purchased Proteon Therapeutics (NASDAQ:PRTO) Shares Three Years Ago Have A 95% Loss To Show For It
  3. Proteon Therapeutics: 1Q Earnings Snapshot
  4. Proteon Therapeutics Announces First Quarter 2019 Financial Results
  5. Proteon exploring sale after 2nd drug trial failure
  6. The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
  7. Proteon Therapeutics Announces Review of Potential Strategic Transactions
  8. Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
  9. Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
  10. Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th
  11. 4 Healthcare Stocks Looking To Set February Highs
  12. Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease
  13. Does The Proteon Therapeutics, Inc. (NASDAQ:PRTO) Share Price Fall With The Market?
  14. New Research Coverage Highlights Yum! Brands, TELUS, Unifi, Proteon Therapeutics, Sabine Royalty Trust, and Algonquin Power & Utilities — Consolidated Revenues, Company Growth, and Expectations for 2018
  15. Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th
  16. Proteon Therapeutics Announces Third Quarter 2018 Financial Results
  17. Is Proteon Therapeutics Inc (NASDAQ:PRTO) A Strong Healthcare Bet?